메뉴 건너뛰기




Volumn 63, Issue 6, 2016, Pages 589-596

Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

Author keywords

Diet therapy; Ipragliflozin; Visceral adipose tissue

Indexed keywords

HEMOGLOBIN A1C; IPRAGLIFLOZIN; WATER; ANTIDIABETIC AGENT; GLUCOSIDE; THIOPHENE DERIVATIVE;

EID: 84976521931     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.EJ15-0749     Document Type: Article
Times cited : (51)

References (20)
  • 1
    • 84976481860 scopus 로고    scopus 로고
    • [accessed Sep 2015]
    • Japan Diabetes Clinical Data Management Study Group (2015) [accessed Sep 2015] Available from: http://jddm. jp/index.html.
    • (2015)
  • 2
    • 0142178067 scopus 로고    scopus 로고
    • Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: A metaanalysis
    • Tanaka S, Horimai C, Katsukawa F (2003) Ethnic differences in abdominal visceral fat accumulation between Japanese, African-Americans, and Caucasians: a metaanalysis. Acta Diabetol 40 Suppl 1: S302-304.
    • (2003) Acta Diabetol , vol.40 , pp. S302-S304
    • Tanaka, S.1    Horimai, C.2    Katsukawa, F.3
  • 3
    • 84904697900 scopus 로고    scopus 로고
    • Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus
    • Kashiwagi A, Kazuta K, Yoshida S, Nagase I (2014) Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig 5: 382-391.
    • (2014) J Diabetes Investig , vol.5 , pp. 382-391
    • Kashiwagi, A.1    Kazuta, K.2    Yoshida, S.3    Nagase, I.4
  • 4
    • 84882251091 scopus 로고    scopus 로고
    • Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis
    • Vasilakou D, Karagiannis T, Athanasiadou E, Mainou M, Liakos A, et al. (2013) Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 159: 262-274.
    • (2013) Ann Intern Med , vol.159 , pp. 262-274
    • Vasilakou, D.1    Karagiannis, T.2    Athanasiadou, E.3    Mainou, M.4    Liakos, A.5
  • 5
    • 33644688031 scopus 로고    scopus 로고
    • Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
    • Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, et al. (2005) Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54: 3427-3434.
    • (2005) Diabetes , vol.54 , pp. 3427-3434
    • Rahmoune, H.1    Thompson, P.W.2    Ward, J.M.3    Smith, C.D.4    Hong, G.5
  • 6
    • 84884167643 scopus 로고    scopus 로고
    • Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
    • Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, et al. (2013) Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet 382: 941-950.
    • (2013) Lancet , vol.382 , pp. 941-950
    • Cefalu, W.T.1    Leiter, L.A.2    Yoon, K.H.3    Arias, P.4    Niskanen, L.5
  • 7
    • 84858020943 scopus 로고    scopus 로고
    • Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin
    • Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, et al. (2012) Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 97: 1020-1031.
    • (2012) J Clin Endocrinol Metab , vol.97 , pp. 1020-1031
    • Bolinder, J.1    Ljunggren, O.2    Kullberg, J.3    Johansson, L.4    Wilding, J.5
  • 8
    • 84892479365 scopus 로고    scopus 로고
    • Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin
    • Bolinder J, Ljunggren O, Johansson L, Wilding J, Langkilde AM, et al. (2014) Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin. Diabetes Obes Metab 16: 159-169.
    • (2014) Diabetes Obes Metab , vol.16 , pp. 159-169
    • Bolinder, J.1    Ljunggren, O.2    Johansson, L.3    Wilding, J.4    Langkilde, A.M.5
  • 9
    • 84864371186 scopus 로고    scopus 로고
    • Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats
    • Devenny JJ, Godonis HE, Harvey SJ, Rooney S, Cullen MJ, et al. (2012) Weight loss induced by chronic dapagliflozin treatment is attenuated by compensatory hyperphagia in diet-induced obese (DIO) rats. Obesity (Silver Spring) 20: 1645-1652.
    • (2012) Obesity (Silver Spring) , vol.20 , pp. 1645-1652
    • Devenny, J.J.1    Godonis, H.E.2    Harvey, S.J.3    Rooney, S.4    Cullen, M.J.5
  • 10
    • 84884554260 scopus 로고    scopus 로고
    • Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice
    • Nagata T, Fukuzawa T, Takeda M, Fukazawa M, Mori T, et al. (2013) Tofogliflozin, a novel sodium-glucose co-transporter 2 inhibitor, improves renal and pancreatic function in db/db mice. Br J Pharmacol 170: 519-531.
    • (2013) Br J Pharmacol , vol.170 , pp. 519-531
    • Nagata, T.1    Fukuzawa, T.2    Takeda, M.3    Fukazawa, M.4    Mori, T.5
  • 11
    • 84951906012 scopus 로고    scopus 로고
    • Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition
    • Ferrannini G, Hach T, Crowe S, Sanghvi A, Hall KD, et al. (2015) Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care 38: 1730-1735.
    • (2015) Diabetes Care , vol.38 , pp. 1730-1735
    • Ferrannini, G.1    Hach, T.2    Crowe, S.3    Sanghvi, A.4    Hall, K.D.5
  • 12
    • 74949093195 scopus 로고    scopus 로고
    • Evolution of sodium glucose cotransporter 2 inhibitors as anti-diabetic agents
    • Washburn WN (2009) Evolution of sodium glucose cotransporter 2 inhibitors as anti-diabetic agents. Expert Opin Ther Pat 19: 1485-1499.
    • (2009) Expert Opin Ther Pat , vol.19 , pp. 1485-1499
    • Washburn, W.N.1
  • 13
    • 77951240013 scopus 로고    scopus 로고
    • Community-based lifestyle modification of cardiovascular disease risks in middle-aged Japanese: A 27-month update
    • Fujii H, Muto T, Haruyama Y, Nakade M, Kobayashi E, et al. (2010) Community-based lifestyle modification of cardiovascular disease risks in middle-aged Japanese: a 27-month update. Tohoku J Exp Med 220: 307-318.
    • (2010) Tohoku J Exp Med , vol.220 , pp. 307-318
    • Fujii, H.1    Muto, T.2    Haruyama, Y.3    Nakade, M.4    Kobayashi, E.5
  • 14
    • 84859097891 scopus 로고    scopus 로고
    • Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan
    • Tajiri Y, Tsuruta M, Ohki T, Kato T, Sasaki Y, et al. (2012) Long-term efficacy of sitagliptin for the treatment of type 2 diabetic patients in Japan. Endocr J 59: 197-204.
    • (2012) Endocr J , vol.59 , pp. 197-204
    • Tajiri, Y.1    Tsuruta, M.2    Ohki, T.3    Kato, T.4    Sasaki, Y.5
  • 17
    • 84908041063 scopus 로고    scopus 로고
    • Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan
    • Muramoto A, Matsushita M, Kato A, Yamamoto N, Koike G, et al. (2014) Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. Obes Res Clin Pract 8: e466-475.
    • (2014) Obes Res Clin Pract , vol.8 , pp. e466-e475
    • Muramoto, A.1    Matsushita, M.2    Kato, A.3    Yamamoto, N.4    Koike, G.5
  • 18
    • 33846092266 scopus 로고    scopus 로고
    • A whole-body model to distinguish excess fluid from the hydration of major body tissues
    • Chamney PW, Wabel P, Moissl UM, Muller MJ, Bosy-Westphal A, et al. (2007) A whole-body model to distinguish excess fluid from the hydration of major body tissues. Am J Clin Nutr 85: 80-89.
    • (2007) Am J Clin Nutr , vol.85 , pp. 80-89
    • Chamney, P.W.1    Wabel, P.2    Moissl, U.M.3    Muller, M.J.4    Bosy-Westphal, A.5
  • 19
    • 0026638094 scopus 로고
    • The five-level model: A new approach to organizing bodycomposition research
    • Wang ZM, Pierson RN Jr, Heymsfield SB (1992) The five-level model: a new approach to organizing bodycomposition research. Am J Clin Nutr 56: 19-28.
    • (1992) Am J Clin Nutr , vol.56 , pp. 19-28
    • Wang, Z.M.1    Pierson, R.N.2    Heymsfield, S.B.3
  • 20
    • 77953870112 scopus 로고    scopus 로고
    • Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People
    • Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, et al. (2010) Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 39: 412-423.
    • (2010) Age Ageing , vol.39 , pp. 412-423
    • Cruz-Jentoft, A.J.1    Baeyens, J.P.2    Bauer, J.M.3    Boirie, Y.4    Cederholm, T.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.